Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10545MR)

This product GTTS-WQ10545MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10545MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2724MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ10072MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ4828MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ9935MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ245MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ9219MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ581MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ6848MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW